1. Home
  2. EYPT vs RVI Comparison

EYPT vs RVI Comparison

Compare EYPT & RVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EYPT

EyePoint Pharmaceuticals Inc.

HOLD

Current Price

$12.55

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Logo Robinhood Ventures Fund I Common Shares of Beneficial Interest

RVI

Robinhood Ventures Fund I Common Shares of Beneficial Interest

N/A

Current Price

$35.70

Market Cap

1.3B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
EYPT
RVI
Founded
1987
N/A
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2005
2026

Fundamental Metrics

Financial Performance
Metric
EYPT
RVI
Price
$12.55
$35.70
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$31.80
N/A
AVG Volume (30 Days)
941.4K
816.1K
Earning Date
05-06-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,539,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3,115.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.37
$22.21
52 Week High
$19.11
$77.39

Technical Indicators

Market Signals
Indicator
EYPT
RVI
Relative Strength Index (RSI) 48.33 41.70
Support Level $12.58 $24.27
Resistance Level $14.73 $63.18
Average True Range (ATR) 0.75 4.79
MACD -0.02 -2.43
Stochastic Oscillator 48.53 5.71

Price Performance

Historical Comparison
EYPT
RVI

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

About RVI Robinhood Ventures Fund I Common Shares of Beneficial Interest

Robinhood Ventures Fund I is a closed-end investment company. The Fund's investment objective is to seek long-term capital appreciation.

Share on Social Networks: